Assessment of mitotic thymus-derived lymphocytes by their sensitivity to the cytotoxic effects of anti-theta serum.

PubWeight™: 1.35‹?› | Rank: Top 10%

🔗 View Article (PMID 4616761)

Published in Cell Immunol on March 30, 1974

Authors

R S Kerbel, E V Elliott, V J Wallis

Articles citing this

Control of the immune response. I. Depression of DNA synthesis by immune lymph node cells. Immunology (1975) 1.29

Studies on hyperlymphoid mice. Immunology (1979) 1.19

The accumulation of immunoblasts in extravascular tissues including mammary gland, peritoneal cavity, gut and skin. Immunology (1978) 1.13

A new sensitive assay for antibody against cell surface antigens based on inhibition of cell-dependent antibody-mediated cytotoxicity. I. Specificity and sensitivity. J Exp Med (1974) 1.11

Studies of hyperthymic mice. I. The influence of multiple thymus grafts on the size of the peripheral T cell pool and immunological performance. Immunology (1978) 1.03

Enumeration of polyclonal mitogen-responsive cells in different lymphoid tissues of the mouse. Immunology (1976) 0.91

T lymphocytes and the transfer of immunity to Trypanosoma musculi in mice. Clin Exp Immunol (1977) 0.87

Selective accumulation of cells with 'B' properties in stimulated lymph nodes. Immunology (1977) 0.84

Ultrastructural and serological studies on the resistance of activated B cells to the cytotoxic effects of anti-immunoglobulin serum. Patch and cap formation of surface immunoglobulin on mitotic B lymphocytes. Clin Exp Immunol (1975) 0.80

Adult and pre-adult thymectomy of mice: contrasting effects on immune responsiveness, and on numbers of mitogen-responsive and Thy-1+ lymphocytes. Immunology (1979) 0.75

The persistent PHA-responsive population in the mouse thymus. II. Recirculatory characteristics and immunological properties. Immunology (1978) 0.75

Genetic control of the proliferative response to oxazolone in H-2 congenic and recombinant strains of mice. Immunology (1979) 0.75

Articles by these authors

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest (2000) 5.52

Establishment and characterization of first trimester human trophoblast cells with extended lifespan. Exp Cell Res (1993) 3.59

Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res (1995) 3.11

Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science (1987) 2.86

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol (1997) 2.82

E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol (1998) 2.81

Peanut lectin binding properties of germinal centres of mouse lymphoid tissue. Nature (1980) 2.79

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res (2001) 2.78

Enhanced immune responsiveness to a thymus-independent antigen early after adult thymectomy: evidence for short-lived inhibitory thymus-derived cells. Eur J Immunol (1972) 2.34

Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents. J Natl Cancer Inst (1994) 2.25

Formation of mouse or sheep red-blood-cell rosettes by lymphocytes from normal and leukaemic individuals. Lancet (1974) 2.18

The possible biological significance of Fc receptors on mammalian lymphocytes and tumor cells. Cell (1974) 2.12

Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun (1999) 1.93

Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. Eur J Cancer (1996) 1.84

Variable effects of anti-lymphocyte serum on humoral antibody formation: role of thymus dependency of antigen. J Immunol (1971) 1.80

TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol (1992) 1.66

Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med (1996) 1.66

A cancer therapy resistant to resistance. Nature (1997) 1.65

Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A (1993) 1.63

Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs (1995) 1.58

Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci U S A (1991) 1.54

Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int J Cancer (1997) 1.48

Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci U S A (1998) 1.47

Neonatal thymectomy and the decrease in antigen-sensitivity of the primary response and immunological "memory" systems. Immunology (1968) 1.46

Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res (1997) 1.45

Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res (2000) 1.42

Effect of cortisone acetate on 19S and 7S haemolysin antibody. A time course study. Immunology (1968) 1.41

The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. Oncogene (1995) 1.40

The trouble with T cells. Lancet (1990) 1.39

Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev (1995) 1.39

Mode of action for anti-lymphocyte serum. Nature (1968) 1.37

Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol (1993) 1.37

Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations. Cancer Res (1988) 1.36

Spontaneous fusion in vivo between normal host and tumor cells: possible contribution to tumor progression and metastasis studied with a lectin-resistant mutant tumor. Mol Cell Biol (1983) 1.32

Heterogeneous vascular dependence of tumor cell populations. Am J Pathol (2001) 1.31

Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells. J Cell Biol (2000) 1.27

Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas. Am J Pathol (1994) 1.27

Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target. Fed Proc (1977) 1.25

Induction of a tumor with greatly increased metastatic growth potential by injection of cells from a low-metastatic H-2 heterozygous tumor cell line into an H-2 incompatible parental strain. Int J Cancer (1978) 1.24

Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res (2000) 1.24

Dok-R plays a pivotal role in angiopoietin-1-dependent cell migration through recruitment and activation of Pak. EMBO J (2001) 1.23

Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol (2002) 1.21

Some effects on leukaemic B lymphocytes of antibodies to defined regions of their surface immunoglobulin. Immunology (1977) 1.21

Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression. J Cell Biol (1995) 1.20

Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci U S A (1992) 1.20

Downregulation of the pro-apoptotic protein Bak is required for the ras-induced transformation of intestinal epithelial cells. Curr Biol (1998) 1.20

Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J Natl Cancer Inst (1996) 1.20

von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res (1998) 1.20

Bronchoconstriction produced in man by leukotrienes C and D. Lancet (1981) 1.19

Studies on hyperlymphoid mice. Immunology (1979) 1.19

Cell adhesion and drug resistance in cancer. Curr Opin Oncol (1997) 1.18

Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol (1998) 1.17

Role of the Fc fragment in the regulation of the primary immune response. Nature (1968) 1.15

Origin and partial characterization of Fc receptor-bearing cells found within experimental carcinomas and sarcomas. Int J Cancer (1975) 1.14

On the sparse seeding of bone marrow and thymus in radiation chimaeras. Transplantation (1975) 1.14

Thymus grafts in thymectomized and normal mice. Nature (1967) 1.13

Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene (2000) 1.12

Development of resistance mechanisms to the growth-inhibitory effects of transforming growth factor-beta during tumor progression. Curr Opin Oncol (1993) 1.12

An assessment of intratumor phagocytic and surface marker-bearing cells in a series of autochthonous and early passaged chemically induced murine sarcomas. J Natl Cancer Inst (1976) 1.11

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer (2008) 1.10

Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int J Cancer (1999) 1.10

Highly pigmented human melanoma variant which metastasizes widely in nude mice, including to skin and brain. Cancer Res (1988) 1.10

Adhesion-dependent multicellular drug resistance. Anticancer Drug Des (1999) 1.09

Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proc Natl Acad Sci U S A (1990) 1.09

TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation between p21Cip1/WAF1 and p27Kip1. Oncogene (1996) 1.09

High-frequency color flow imaging of the microcirculation. Ultrasound Med Biol (2000) 1.09

Further studies of antigenic competition. 3. A model to account for the phenomenon based on a deficiency of cell-to-cell interaction in immune lymphoid cell populations. J Exp Med (1971) 1.08

Dominance of metastatically competent cells in primary murine breast neoplasms is necessary for distant metastatic spread. Int J Cancer (1991) 1.08

Neoplasms arising in CBA mice after transfer of spleen cells from syngeneic old donors. Immunology (1984) 1.07

Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas. Clin Cancer Res (1998) 1.06

The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res (1995) 1.06

Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Investig Dermatol Symp Proc (2000) 1.06

Enhanced tumorigenicity, melanogenesis, and metastases of a human malignant melanoma after subdermal implantation in nude mice. J Natl Cancer Inst (1989) 1.06

Genetic tagging of tumor cells with retrovirus vectors: clonal analysis of tumor growth and metastasis in vivo. Mol Cell Biol (1988) 1.06

Lymphocyte: erythrocyte (L.E.) rosettes as indicators of the heterogeneity of lymphocytes in a variety of mammalian species. Cell (1975) 1.05

Immunologic studies of membrane mutants of a highly metastatic murine tumor. Am J Pathol (1979) 1.05

Mutagen treatment as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors. Cancer Res (1983) 1.04

Studies of hyperthymic mice. I. The influence of multiple thymus grafts on the size of the peripheral T cell pool and immunological performance. Immunology (1978) 1.03

Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression. J Cell Physiol (1994) 1.02

Implications of immunological heterogeneity of tumours. Nature (1979) 1.01

Characterization of a deficiency in fucose metabolism in lectin-resistant variants of a murine tumor showing altered tumorigenic and metastatic capacities in vivo. Cancer Res (1981) 1.01

Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells. Cancer Res (1992) 1.01

Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. Cancer Lett (1998) 0.99

Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl-X(L). Cancer Res (2001) 0.99

Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls. Cancer Metastasis Rev (1996) 0.98

bFGF and tumor angiogenesis--back in the limelight? Nat Med (1997) 0.98

Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. Oncogene (1999) 0.98

Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol (2005) 0.97

Rosette formation by a mouse fibroblast cell line. Nature (1974) 0.96

Apparent reversion of stable in vitro genetic markers detected in tumour cells from spontaneous metastases. Nature (1981) 0.96

On a possible epigenetic mechanism(s) of tumor cell heterogeneity. The role of DNA methylation. Cancer Metastasis Rev (1983) 0.95

Origin of PHA-responsive cells in the mouse thymus after treatment of the animal with hydrocortisone. Nat New Biol (1971) 0.95

Resistance of malignant trophoblast cells to both the anti-proliferative and anti-invasive effects of transforming growth factor-beta. Exp Cell Res (1994) 0.94

Further studies of competition of antigens. I. Variation in immunosuppression induced by alterations of dosage, route of injection, nature of antigen, and immunological status of host. Can J Microbiol (1971) 0.94

Extensive multi-organ metastasis following orthotopic onplantation of histologically-intact human bladder carcinoma tissue in nude mice. Int J Cancer (1991) 0.94

Selection of strongly immunogenic "tum-" variants from tumors at high frequency using 5-azacytidine. J Exp Med (1984) 0.94

Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications. Oncogene (2000) 0.94